All In Biotech

Drug Trial Radar · NCT03409744

Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Last checked: Nov 20, 2026Latest source record: Apr 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

116

Actual

Start

Mar 13, 2018

Primary completion

Apr 13, 2023

Study completion Apr 13, 2023

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Jan 24, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of the study are: * To evaluate the long-term safety and tolerability of evinacumab in patients with Homozygous Familial Hypercholesterolemia (HoFH) * To evaluate the long-term safety and tolerability of evinacumab in adolescent patients with HoFH The secondary objectives of the study are: * To evaluate the effect of evinacumab on lipid parameters in patients with HoFH * To evaluate the effect of evinacumab on lipid parameters in adolescent patients with HoFH * To evaluate the potential development of anti-evinacumab antibodies

Conditions

  • Homozygous Familial Hypercholesterolemia

Interventions

  • evinacumabDrug

    Intravenous (IV) administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Up to Week 216Time frame: Up to 216 weeks

Locations

38 sites in 12 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Los Angeles, California

  • Clinical Trial Site

    Boca Raton, Florida

  • Clinical Trial Site

    Boston, Massachusetts

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    Cincinnati, Ohio

  • Clinical Trial Site

    Portland, Oregon

  • Clinical Trial Site

    Philadelphia, Pennsylvania

  • Clinical Trial Site

    Dallas, Texas

  • Clinical Trial Site

    Dallas, Texas

  • Clinical Trial Site

    Camperdown, New South Wales, Australia

  • Clinical Trial Site

    Perth, Western Australia, Australia

  • Regeneron Study Site

    Innsbruck, Austria

  • Regeneron Study Site

    Vienna, State of Vienna, Austria

  • Clinical Trial Site

    Québec, Canada

  • Clinical Trial Site

    Chicoutimi, Quebec, Canada

  • Regeneron Study Site

    Prague, Kateřinská, Czechia

  • Clinical Trial Site

    Dijon, Cedex, France

  • Clinical Trial Site

    Paris, Cedex 13, France

  • Clinical Trial Site

    Marseille, Cedex 5, France

  • Clinical Trial Site

    Ioannina, Greece

  • Regeneron Study Site

    Kallithea, Athens, Greece

  • Clinical Trial Site

    Naples, Campania, Italy

  • Clinical Trial Site

    Roma, Rome, Italy

  • Clinical Trial Site

    Ōbu, Aichi-ken, Japan

  • Regeneron Study Site

    Kurume, Fukuoka, Japan

  • Regeneron Study Site

    Nishinomiya, Hyōgo, Japan

  • Regeneron Study Site

    Kanazawa, Ishikawa-ken, Japan

  • Regeneron Study Site

    Kita-ku, Osaka, Japan

  • Regeneron Study Site

    Suita, Osaka, Japan

  • Regeneron Study Site

    Suita, Osaka, Japan

  • Clinical Trial Site

    Amsterdam, Netherlands

  • Regeneron Study Site

    Johannesburg, Gauteng, South Africa

  • Regeneron Study Site

    Cape Town, Western Cape, South Africa

  • Clinical Trial Site

    Ivano-Frankivsk, Ukraine

  • Clinical Trial Site #1

    Kharkiv, Ukraine

  • Clinical Trial Site #2

    Kharkiv, Ukraine

  • Clinical Trial Site

    Kyiv, Ukraine

  • Rgeneron Study Site

    Kyiv, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.